Dougherty & Co Downgrades Integramed America (INMD) to Sell; Acquired By Sagard Capital Partners
Get Alerts INMD Hot Sheet
Price: $17.45 -0.96%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: Up
Today's Overall Ratings:
Up: 11 | Down: 13 | New: 18
Join SI Premium – FREE
Dougherty & Co downgraded Integramed America (NASDAQ: INMD) from Buy to Sell with a price target of $14.05 (from $15.50).
Analyst, Brooks O'Neil, said, "IntegraMed America, Inc. announced today that it has entered into a definitive agreement to be acquired by affiliates formed by Sagard Capital Partners, L.P. (“Sagard Capital”), an investment fund and IntegraMed shareholder, for $14.05 per share in cash, or a total equity purchase price of $169.5 million. The consideration represents a 24% premium to IntegraMed’s closing stock price of $11.34 on Friday, June 8, 2012, the last trading day prior to today’s announcement...We expect this transaction to be completed and thus, we think the shares will trade at only a small discount to the ultimate acquisition price...We believe the company conducted a process to explore its strategic alternatives, and that Sagard offered the best option. Thus, we do not expect a higher bid,"
For an analyst ratings summary and ratings history on Integramed America click here. For more ratings news on Integramed America click here.
Shares of Integramed America closed at $11.34 yesterday.
Analyst, Brooks O'Neil, said, "IntegraMed America, Inc. announced today that it has entered into a definitive agreement to be acquired by affiliates formed by Sagard Capital Partners, L.P. (“Sagard Capital”), an investment fund and IntegraMed shareholder, for $14.05 per share in cash, or a total equity purchase price of $169.5 million. The consideration represents a 24% premium to IntegraMed’s closing stock price of $11.34 on Friday, June 8, 2012, the last trading day prior to today’s announcement...We expect this transaction to be completed and thus, we think the shares will trade at only a small discount to the ultimate acquisition price...We believe the company conducted a process to explore its strategic alternatives, and that Sagard offered the best option. Thus, we do not expect a higher bid,"
For an analyst ratings summary and ratings history on Integramed America click here. For more ratings news on Integramed America click here.
Shares of Integramed America closed at $11.34 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citi Downgrades Arch Coal (ARCH) to Neutral
- UBS Downgrades Beijing Easpring Material Technology Co Ltd. (300073:CH) to Neutral
- Zuora (ZUO) Exploring a Potential Interest After Receiving Acquisition Interest from Potential Buyers - Reuters
Create E-mail Alert Related Categories
Downgrades, Mergers and AcquisitionsRelated Entities
Sagard Capital PartnersSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!